Recruiting

Observational Study

Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Code:

NCT00071526

Conditions

Diabetes

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Study Details

Brief summary:

Several studies have reported that diabetic subjects have lower plasma vitamin C concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic subjects was reported to be increased in two studies, these are difficult to interpret due to lack of controlled vitamin C intake, inadequate sampling, lack of control subjects, or methodology uncertainties in vitamin C assay and sample processing. Consequently, it is unclear whether diabetic subjects truly have both low plasma and high urine vitamin C concentrations. We propose that low plasma vitamin C concentrations in diabetic subjects are due in part to inappropriate renal loss of vitamin C in these subjects but not in healthy controls. We will study nondiabetic controls and cohorts with diabetes. Vitamin C concentrations in plasma, RBCs, and urine will be measured in outpatients. In those willing to be admitted to the Clinical Center, we will measure vitamin C pharmacokinetics to determine the relative bioavailability for vitamin C in individuals with and without abnormal urinary loss of vitamin C (or renal leak). Single nucleotide polymorphisms (SNPs) will be determined in genomic DNA responsible for the two proteins mediating sodium dependent vitamin C transport, SVCT1 and SVCT2. We will also explore mechanisms underlying abnormal urinary vitamin C loss.

Conditions

Diabetes

Study ID

NCT00071526

Start date

Apr 11, 2006

Status verified date

Aug 26, 2026

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

  • INCLUSION CRITERIA:

To be included in the study, study subjects should be:

  • Aged 18-65 years.
  • Either:

  • Have no diagnosis of diabetes: "nondiabetic controls", or
  • Have a diagnosis in their medical history of either Type 1 or Type 2 diabetes

EXCLUSION CRITERIA (for outpatient study, arm 1)

Exclusion criteria will include the following:

  • Unable or unwilling to provide a signed and dated informed consent form
  • Unable or unwilling to comply with study procedures and lifestyle considerations

EXCLUSION CRITERIA (for inpatient studies, arms 2 and 3)

Study participants interested in participating in Arms 2 and/or 3 will be excluded from this further participation if they meet any of the following:

  • significant organ malfunction leading to clinical instability including liver disease, pulmonary disease, ischemic heart disease, heart failure, stroke, peripheral vascular disease, and anemia at investigator discretion
  • other serious or chronic illness; history of serious or chronic illness; coronary artery disease, or peripheral vascular disease resulting in clinical instability
  • pregnancy or lactation
  • presence of other conditions which, in the judgment of the investigators, can influence vitamin C metabolism or vitamin C renal handling

Study Design

Enrollment

5000 participants

Anticipated

Interventions and Outcome Measures

Arms

Diabetes Type I

Subjects with Type I diabetes mellitus

Diabetes Type II

Subjects with Type II diabetes mellitus

Healthy Volunteers

Healthy Volunteers

Primary outcome measure

  • Plasma, neutrophil and RBC Vitamin C concentrates [ Time Frame: end of study ]

Central Contacts and Locations

Central contacts

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

More Information

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Last update posted

Aug 31, 2026

Last verified

Aug 26, 2026

Keywords

  • Renal Threshold
  • Diabetes Mellitus
  • Proteinuria
  • Plasma Concentrations
  • Healthy Volunteer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on 2026-08-31.